WCLC 2023 | MET fusions as a therapeutic target in NSCLC

Chul Kim, MD, MPH, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, discusses how MET alterations that lead to MET pathway activation are an important characteristic of various types of cancer, including non-small cell lung cancer (NSCLC), and how MET fusions are a potential therapeutic target. Dr Kim shares findings on the prevalence of MET fusions in different cancers, where MET fusions were seen in about 0.1% of cases of NSCLC and almost exclusively in lung adenocarcinomas. It was also concluded that there are potentially two categories of MET fusion: primary driver mutations or secondary acquired resistance mutations. Dr Kim also highlights the clinical importance of this research as evidenced by MET fusion-positive patients with NSCLC exhibiting a shorter overall survival rate compared to MET fusion-negative NSCLC patients. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.